Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Phase 3rexlemestrocel-LPositive

AI Analysis

Summary

Mesoblast completed patient treatment in its Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain, enrolling 350 patients in the randomized controlled study. The company increased patient numbers from 300 to 350 due to strong investigator demand.

Clinical Trial Data

Phase

Phase 3

Patients

350

Outcome Details

completed patient treatment in MSB-DR004 pivotal Phase 3 trial

Importance:6/10

Sentiment:

0.70

Phase 3allogeneic cellular medicinechronic low back paindegenerative disc diseaseintra-discal injectionmilestone

Related Companies

$MESO

Read the original article

Published by GlobeNewswire Clinical Studies on August 17, 2026 12:35 AM

Read Original